Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Personalis, Inc. - Common Stock (NQ:PSNL)

12.95 -0.49 (-3.65%)

Streaming Delayed Price Updated: 1:21 PM EDT, Jul 22, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	1,176,650
Open	13.34
Bid (Size)	12.94 (700)
Ask (Size)	12.95 (100)
Prev. Close	13.44
Today's Range	12.84 - 13.41
52wk Range	3.840 - 16.39
Shares Outstanding	48,518,901
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Halper Sadeh LLC is Investigating Whether UTZ, PSNL, LXP are Obtaining Fair Deals for their Shareholders

Today 9:06 EDT

From Halper Sadeh LLC

Via GlobeNewswire

Personalis Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Personalis, Inc. - PSNL

July 21, 2026

From Kahn Swick & Foti, LLC

Via Business Wire

Performance

YTD	+65.0%	+65.0%
1 Month	+27.3%	+27.3%
3 Month	+107.5%	+107.5%
6 Month	+37.9%	+37.9%
1 Year	+108.9%	+108.9%

More News

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Personalis, Inc. (Nasdaq – PSNL), Distribution Solutions Group, Inc. (Nasdaq – DSGR), Cross Country Healthcare, Inc. (Nasdaq – CCRN), Nuvalent, Inc. (Nasdaq – NUVL)

July 21, 2026

From Brodsky & Smith LLC

Via GlobeNewswire

Personalis (NASDAQ:PSNL) Volume Surge Can't Mask Q1 Miss as Losses Widen ↗

May 07, 2026

Via Chartmill

PSNL Stock Alert: Halper Sadeh LLC is Investigating Whether Personalis, Inc. is Obtaining a Fair Price for Shareholders

July 20, 2026

From Halper Sadeh LLC

Via Business Wire

Tempus to Acquire Personalis, More Tightly Integrating Molecular Residual Disease (MRD) into Its AI-Enabled Precision Oncology Platform

July 20, 2026

From Personalis, Inc.

Via Business Wire

Personalis Accelerates Global Expansion with UKCA Marking for NeXT Personal®, Expanding MRD Access and Biopharma Support in Great Britain

July 14, 2026

From Personalis, Inc.

Via Business Wire

Personalis Enables Global Biopharma Support with CE-IVD Marked Specimen Collection Kits

June 09, 2026

From Personalis, Inc.

Via Business Wire

Personalis CEO Sells 100,000 Company Shares Worth $1.1 Million. What Does That Mean for Investors? ↗

June 04, 2026

Via The Motley Fool

Personalis Highlights Early Colorectal Cancer Recurrence Detection and Ultrasensitive MRD Performance Across a Broad Set of Tumor Types at ASCO 2026

June 02, 2026

From Personalis, Inc.

Via Business Wire

Personalis to Highlight Breadth of NeXT Personal® Ultra-Sensitive ctDNA Data at ASCO 2026 Annual Meeting, Including Podium Presentation from TRACERx Consortium

May 26, 2026

From Personalis, Inc.

Via Business Wire

Personalis Secures Fourth Medicare Coverage Decision for NeXT Personal®, Expanding Breast Cancer Coverage to Pre-Surgical Treatment Monitoring

May 20, 2026

From Personalis, Inc.

Via Business Wire

Personalis to Participate in Upcoming Investor Events

May 14, 2026

From Personalis, Inc.

Via Business Wire

Personalis Receives Medicare Coverage for NeXT Personal® for Immunotherapy Monitoring Across Late-stage Solid Tumors

May 13, 2026

From Personalis, Inc.

Via Business Wire

Personalis Q1 Earnings Call Highlights ↗

May 08, 2026

Via MarketBeat

Personalis (PSNL) Q1 2026 Earnings Transcript ↗

May 08, 2026

Via The Motley Fool

Personalis Reports First Quarter Results and Recent Highlights

May 07, 2026

From Personalis, Inc.

Via Business Wire

Personalis to Announce First Quarter 2026 Financial Results

April 23, 2026

From Personalis, Inc.

Via Business Wire

Personalis Highlights Clinical Impact of Ultrasensitive ctDNA Monitoring and New Therapy Resistance Tracking at AACR 2026

April 21, 2026

From Personalis, Inc.

Via Business Wire

Personalis and Collaborators to Highlight Ultrasensitive ctDNA Data and New Therapy Resistance Tracking Capabilities at AACR 2026

April 13, 2026

From Personalis, Inc.

Via Business Wire

Personalis to Participate in the 25th Annual Needham Virtual Conference

April 01, 2026

From Personalis, Inc.

Via Business Wire

Personalis Appoints Dr. Richard Chen as President to Further Accelerate MRD Adoption

March 17, 2026

From Personalis, Inc.

Via Business Wire

Personalis Announces New Publication Advancing Neoadjuvant Treatment Monitoring in Breast Cancer with NeXT Personal®

March 12, 2026

From Personalis, Inc.

Via Business Wire

Lightspeed Makes a Big Bet on Self-Driving Trucks, Loading Up on 7 Million Shares of Kodiak AI (KDK) ↗

March 01, 2026

Via The Motley Fool

Lightspeed Management Made a Huge Bet on Navan (NAVN) With a Purchase of 49.9 Million Shares ↗

March 01, 2026

Via The Motley Fool

Frequently Asked Questions

Is Personalis, Inc. - Common Stock publicly traded?

Yes, Personalis, Inc. - Common Stock is publicly traded.

What exchange does Personalis, Inc. - Common Stock trade on?

Personalis, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Personalis, Inc. - Common Stock?

The ticker symbol for Personalis, Inc. - Common Stock is PSNL on the Nasdaq Stock Market

What is the current price of Personalis, Inc. - Common Stock?

The current price of Personalis, Inc. - Common Stock is 12.95

When was Personalis, Inc. - Common Stock last traded?

The last trade of Personalis, Inc. - Common Stock was at 07/22/26 01:21 PM ET

What is the market capitalization of Personalis, Inc. - Common Stock?

The market capitalization of Personalis, Inc. - Common Stock is 628.32M

How many shares of Personalis, Inc. - Common Stock are outstanding?

Personalis, Inc. - Common Stock has 628M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.